[Correspondence] Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer – Authors' response

Huillard and colleagues provide a report of a patient with BRAFV600E mutated tall-cell variant papillary thyroid carcinoma who experienced a complete response after being treated with vemurafenib followed by radioactive iodine. This patient's disease converted from radioiodine non-avid to avid after the administration of vemurafenib. The authors speculate that vemurafenib might have a direct anti-tumour effect and re-sensitise tumour cells to radioactive iodine by affecting sodium iodide symporters that are dysregulated in BRAFV600E disease.

http://ift.tt/2eO9Wvs